New device could diagnose fatty liver without needles

NCT ID NCT02575625

First seen Jun 22, 2026 · Last updated Jun 22, 2026

Summary

This study tests whether a device called Fibroscan can diagnose fatty liver disease (steatosis) without needing a biopsy. Researchers will measure liver stiffness and viscosity in 72 people, including healthy volunteers and patients with confirmed fatty liver. Results will be compared with MRI scans and blood tests to see if Fibroscan is a reliable alternative.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LIVER STEATOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • University Hospital of Tours

    Tours, 37044, France

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this could provide a non-invasive way to diagnose fatty liver disease, reducing the need for liver biopsies.

What could go wrong

This is a small, early-stage study with only 72 participants. The method may not be accurate enough to replace current diagnostic tools.

Conditions

The condition(s) this trial relates to.

Fatty Liver

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.